Status:
COMPLETED
Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early Mild Symptoms of COVID-19
Lead Sponsor:
King Edward Medical University
Conditions:
COVID-19
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Quercetin is a flavonoid dietary supplement that occurs in many edible fruits and vegetables. It has remarkable antioxidant, anti-inflammatory, immunoprotective and antiviral properties. It is widely ...
Detailed Description
The strong antioxidant and anti-inflammatory properties of quercetin are closely related to its effective fight against a variety of disease conditions related to inflammation, including: viral infect...
Eligibility Criteria
Inclusion
- Patients must be 18 years of age or older, of either gender
- Patients must be tested positive for SARS-CoV-2 by RT-PCR
- Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes with shaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.
- Patients must be in the early stage of COVID-19 disease who do not require hospitalisation at the time of screening
- Patients must be under the care of a Physician for diagnosis of COVID-19
- Patients who have signed informed consent
Exclusion
- Patients with proven hypersensitivity or allergic reaction to quercetin
- Patients with known chronic kidney disease with estimated creatinine clearance \< 50 mL/minute or need for dialysis
- Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure
- Patients with moderate or severe thrombocytopenia (platelet count \<100 × 10⁹/L);
- Pregnant patients
- Patients declining to participate
Key Trial Info
Start Date :
January 11 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 29 2021
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT04861298
Start Date
January 11 2021
End Date
August 29 2021
Last Update
February 7 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
King Edward Medical University Teaching Hospital
Lahore, Punjab Province, Pakistan, 54000